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1. INTRODUCTION {#cas13529-sec-0001}
===============

Hepatocellular carcinoma (HCC) is the 5th most prevalent cancer and a leading cause of cancer death worldwide.[1](#cas13529-bib-0001){ref-type="ref"} Although the most frequent etiology for HCC is viral infections such as the hepatitis B and C viruses, the prevalence of HCC without viral infection is increasing in Western countries[2](#cas13529-bib-0002){ref-type="ref"} and Japan.[3](#cas13529-bib-0003){ref-type="ref"} In developed countries, 30%‐40% of HCC cases arise from the liver without viral infection,[4](#cas13529-bib-0004){ref-type="ref"} suggesting a higher prevalence of metabolic syndrome with non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) associated with the development of HCC.[5](#cas13529-bib-0005){ref-type="ref"}, [6](#cas13529-bib-0006){ref-type="ref"}

Non‐B non‐C HCC (NHCC) and HCC with viral infection (VHCC) in advanced stages are currently treated in the same manner; however, their pathological features sometimes differ, such as the abundant deposition of triglycerides (TG) including a steatohepatitic appearance,[7](#cas13529-bib-0007){ref-type="ref"} which is commonly reported in NHCC. TG are composed of 3 fatty acids (FA) and glycerol, and their accumulation is the hallmark of NASH,[8](#cas13529-bib-0008){ref-type="ref"}, [9](#cas13529-bib-0009){ref-type="ref"} resulting in hepatic dysfunction, such as insulin resistance.[10](#cas13529-bib-0010){ref-type="ref"}, [11](#cas13529-bib-0011){ref-type="ref"} Previous studies have demonstrated that hepatic TG themselves are not toxic and may protect the liver from FA‐induced lipotoxicity,[12](#cas13529-bib-0012){ref-type="ref"} but lipogenesis has an important role in cellular survival of HCC.[13](#cas13529-bib-0013){ref-type="ref"} However, the toxic effects of FA on hepatic cancer cells have not yet been examined in detail.

Saturated FA (SFA), including palmitate (C16:0; PA) and stearate (C18:0; SA), exert toxic effects on living cells by inducing endoplasmic reticulum (ER) stress,[14](#cas13529-bib-0014){ref-type="ref"}, [15](#cas13529-bib-0015){ref-type="ref"} which leads to cell apoptosis. However, monounsaturated FA (MUFA), such as oleate (C18:1n9; OA), have been shown to alleviate SFA‐induced deleterious effects.[16](#cas13529-bib-0016){ref-type="ref"}, [17](#cas13529-bib-0017){ref-type="ref"} Although FA composition ratios such as the MUFA‐to‐SFA ratio are an important factor for cancer cell survival,[18](#cas13529-bib-0018){ref-type="ref"}, [19](#cas13529-bib-0019){ref-type="ref"}, [20](#cas13529-bib-0020){ref-type="ref"} limited information is currently available on SFA composition ratios. PA is synthesized through acetate polymerization in de novo lipogenesis.[21](#cas13529-bib-0021){ref-type="ref"} This long chain FA is then endogenously converted to SA by elongation of very long‐chain fatty acids family member 6 (ELOVL6), or shifted to MUFA by stearoyl‐CoA desaturase 1 (SCD‐1) in the ER.[22](#cas13529-bib-0022){ref-type="ref"} ELOVL6 is a microsomal enzyme that alters the stearate‐to‐palmitate ratio (SPR) and has also been shown to mediate the progression of NASH.[23](#cas13529-bib-0023){ref-type="ref"}, [24](#cas13529-bib-0024){ref-type="ref"}, [25](#cas13529-bib-0025){ref-type="ref"}

We herein examined SPR in the cancerous parts (CA) and adjacent non‐cancerous parenchyma (NC) of NHCC using matrix‐assisted laser desorption/ionization imaging mass spectrometry (MALDI‐IMS), and the relationship between SPR and the expression of ELOVL6 and SCD1. We also investigated the involvement of SPR in cancer progression using the hepatoma cell lines, Huh7 and HepG2, to clarify whether the results obtained may be applied to the development of therapeutic approaches for NHCC.

2. MATERIALS AND METHODS {#cas13529-sec-0002}
========================

2.1. Patients {#cas13529-sec-0003}
-------------

This study was performed with the approval of the Institutional Ethics Committee of Hamamatsu University School of Medicine, and written informed consent was obtained from all patients. Fifteen HCC specimens were collected from patients undergoing hepatectomy for curative intent at Hamamatsu University Hospital between 2010 and 2012.

2.2. Imaging mass spectrometry for human liver samples {#cas13529-sec-0004}
------------------------------------------------------

Fifteen 10‐μm‐thick frozen HCC specimens were placed on indium‐tin oxide (ITO)‐coated glass slides (Bruker Daltonics, Bremen, Germany). As a matrix, 5 mg/mL of 9‐aminoacridine in 70% methanol (Merck, Darmstadt, Germany) was sprayed on the samples as previously described.[26](#cas13529-bib-0026){ref-type="ref"}, [27](#cas13529-bib-0027){ref-type="ref"}, [28](#cas13529-bib-0028){ref-type="ref"}, [29](#cas13529-bib-0029){ref-type="ref"} Mass spectrometry (MS) was performed with a matrix‐assisted laser desorption/ionization time‐of‐flight (MALDI‐TOF/TOF) type instrument, the Ultraflex II (Bruker Daltonics). MS parameters were set to obtain the highest sensitivity with *m*/*z* values in the range of 200‐1000 in the negative‐ion mode. The automatic acquisition of spectra and reconstruction of ion images were performed using FlexImaging Software (Bruker Daltonics).

2.3. Cell cultures {#cas13529-sec-0005}
------------------

The human HCC cell lines Huh7 and HepG2 were maintained in DMEM (Invitrogen, Carlsbad, CA, USA) with 10% FBS, 100 U penicillin, and 0.1 mg/mL streptomycin at 37°C in a 5% CO~2~ atmosphere.

2.4. Immunoblotting {#cas13529-sec-0006}
-------------------

Rabbit polyclonal anti‐ELOVL6 (Millipore Corporation, Billerica, MA, USA), mouse monoclonal anti‐SCD1 (Abcam Tokyo, Japan), rabbit polyclonal anti‐PARP, mouse monoclonal anti‐caspase‐3, rabbit polyclonal anti‐cleaved caspase‐3, rabbit monoclonal anti‐PERK, rabbit monoclonal anti‐phospho‐PERK, and rabbit monoclonal anti‐beta‐actin for an internal standard (Cell Signaling Technology, Beverly, MA, USA) were used. Immunoreactive proteins were detected using an enhanced chemiluminescence system (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and an LAS‐3000 Luminescent Image Analyzer (Fujifilm, Tokyo, Japan).

2.5. Quantitative RT‐PCR {#cas13529-sec-0007}
------------------------

Total RNA was extracted from liver specimens and cells using ISOGEN (Nippon Gene, Tokyo, Japan) and the RNeasy Mini Kit (QIAGEN, Valencia, CA). mRNA were reverse transcribed to complementary DNA with the PrimeScript RT Reagent Kit (TAKARA BIO, Shiga, Japan). A quantitative RT‐PCR analysis was performed with the Thermal Cycler Dice Real Time System Single (TAKARA) using SYBR green as a fluorophore. PCR primers were listed in Table [S1](#cas13529-sup-0001){ref-type="supplementary-material"}. The expression of target mRNA was normalized to the expression level of cyclophilin A (*PPIA*).

2.6. Immunofluorescence and a TUNEL assay for cell lines {#cas13529-sec-0008}
--------------------------------------------------------

Cells were fixed with 4% paraformaldehyde (PFA), washed with PBS, and immersed in PBS containing 5% goat serum and 0.1% Triton X‐100 for blocking and permeabilization. A rabbit polyclonal anti‐ELOVL6 antibody (1:300, Santa Cruz, CA, USA) and mouse monoclonal anti‐Calnexin antibody (1:1000, Abcam Tokyo, Japan) were used as primary antibodies, followed by Alexa Fluormconjugated secondary antibodies (1:1000, Abcam). In the TUNEL assay, an In Situ Apoptosis Detection Kit (Takara) was used according to the manufacturer\'s instructions. Samples were mounted in VECTASHIELD (Vector Laboratories, Burlingame, CA, USA), and fluorescence images were obtained using the confocal microscope FV1000 (OLYMPUS, Tokyo, Japan).

2.7. Preparation of cells for imaging mass spectrometry {#cas13529-sec-0009}
-------------------------------------------------------

To perform IMS, 5 × 10^5^ cells were incubated on ITO‐coated slide glasses shielded by a rounded silicone rubber with a 15‐mm pore for 10 hours. Cells were fixed with 4% PFA and washed with 150 mmol/L ammonium acetate 3 times. Slides were desiccated and cellular lipids were analyzed by Ultraflex II.

2.8. Fatty acid preparation {#cas13529-sec-0010}
---------------------------

Palmitate (PA) and stearate (SA) were purchased from Wako. Each FA stock solution was prepared as previously described.[30](#cas13529-bib-0030){ref-type="ref"} Stock solutions of 100 mmol/L PA and SA dissolved in 0.1 mol/L sodium hydroxide were heated at 75°C, then added to DMEM containing 3% FA‐free BSA (Sigma Aldrich, Munich, Germany) pre‐heated at 55°C.[31](#cas13529-bib-0031){ref-type="ref"} The final concentrations of the working solutions were 2 mmol/L PA and SA. After filtration of the working solutions, they were diluted in DMEM for adjustments to the indicated concentrations.

2.9. Modulation of Elovl6 activity with siRNA {#cas13529-sec-0011}
---------------------------------------------

In the small interfering RNA inhibition assay, Huh7 and HepG2 cells were knocked down using Stealth RNAi (Invitrogen) against human *ELOVL6*, the sequences of which were 5′‐CGCUGCUCUUCGAACUGCUGCUUAU‐3′ and 5′‐AUAAGCACCAGUUCG‐AAGAGCACCG‐3′. RNAi Negative Control Medium GC Duplex (Invitrogen) was used as a negative control. Cells were transfected with Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer\'s instructions, and were incubated for 48 hours. Media were changed to DMEM containing 0.6 mmol/L PA, and cells were harvested 24 hours after the medium change.

2.10. Cell proliferation assay {#cas13529-sec-0012}
------------------------------

In knockdown experiments, 8 × 10^3^ Huh7 cells and 5 × 10^3^ HepG2 cells were plated on 96‐well plates. Cell proliferation was measured 3 days after the completion of knockdown. The XTT Cell Proliferation Kit (Roche Applied Science, Penzberg, Germany) was used according to the manufacturer\'s instructions. The absorbance of live cells was measured with the Synergy HT Multi‐Mode Microplate Reader (BioTek, Winooski, VT, USA).

2.11. Statistical analysis {#cas13529-sec-0013}
--------------------------

Statistical analyses were performed with SPSS Statistics software (version 21; SPSS, Chicago, USA). Results are expressed as the mean ± SEM of at least 3 independent experiments. The χ^2^‐test and Mann‐Whitney *U*‐test were used for analyses of clinical and histological features. The Wilcoxon signed‐rank test was used for IMS and western blotting analyses. The *t* test and a univariate analysis of variance (ANOVA, Bonferroni procedure) were used to test for differences between 2 and more groups of samples, respectively. The relationship between SPR and ELOVL6 expression in the immunoblot analysis was tested by Spearman\'s rank correlation coefficient. *P *\< .05 was considered to indicate a significant difference.

3. RESULTS {#cas13529-sec-0014}
==========

3.1. NHCC patients were more likely to have steatosis in liver parenchyma {#cas13529-sec-0015}
-------------------------------------------------------------------------

The clinicopathological features of 15 HCC patients are shown in Table [1](#cas13529-tbl-0001){ref-type="table-wrap"}. Macrovesicular steatosis and ballooning, which are commonly observed in steatohepatitic HCC, were more frequently detected histologically in NHCC cancer (Figure [S1](#cas13529-sup-0001){ref-type="supplementary-material"}).[7](#cas13529-bib-0007){ref-type="ref"} Five NHCC samples did not exhibit other historical hepatitis, such as autoimmune hepatitis.

###### 

Clinicopathological features of 15 patients with HCC

                             NHCC           VHCC           *P*‐value
  -------------------------- -------------- -------------- -----------
  Patient number             5              10             
  Gender (M/F)               5/0            7/3            NS
  Age (years)                71.2 ± 2.85    68.3 ± 2.35    NS
  BMI (kg/m^2^)              23.9 ± 1.02    22.4 ± 0.78    NS
  Alcohol (y/n)              1/4            2/8            NS
  Alb (g/dL)                 4.3 ± 0.10     4.2 ± 0.10     NS
  T. bil (mg/dL)             0.94 ± 0.24    1.05 ± 0.12    NS
  AST (IU/L)                 53.0 ± 10.3    43.8 ± 6.57    NS
  ALT (IU/L)                 49.2 ± 12.5    38.0 ± 9.88    NS
  PT (%)                     84.8 ± 6.94    89.1 ± 4.62    NS
  ICG R15 (%)                17.8 ± 9.49    18.0 ± 3.85    NS
  HbA1c (%)                  6.08 ± 0.25    5.76 ± 0.23    NS
  TG (mg/dL)                 223.0 ± 94.1   130.6 ± 15.4   NS
  T. chol (mg/dL)            176.8 ± 11.4   174.3 ± 12.0   NS
  Tumor number (s/m)         3/2            7/3            NS
  Tumor size (cm)            3.2 ± 0.45     3.5 ± 0.57     NS
  Differentiation (w/m/p)    1/3/1          1/9/0          NS
  Vessel invasion (y/n)      3/2            4/6            NS
  Liver cirrhosis (y/n)      3/2            2/8            NS
  Hepatitis activity score   1.6 ± 0.40     1.5 ± 0.17     NS
  Fibrosis score             2.4 ± 0.51     2.6 ± 0.45     NS
  UICC Stage (I/II/III)      1/1/3          1/5/4          NS

Alcohol, ethanol consumption of more than 20 g/day; BMI, body mass index; Differentiation, well‐differentiated (w), moderately differentiated (m) and poorly differentiated (p); NHCC, HCC without viral infections; Tumor N, tumor number indicating a solitary (s) or multiple (m) tumors; VHCC, hepatocellular carcinoma (HCC) with viral infections. The clinical stage was assessed according to the UICC Classification.
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3.2. Saturated fatty acid signals identified by imaging mass spectrometry were altered in the cancerous parts of NHCC {#cas13529-sec-0016}
---------------------------------------------------------------------------------------------------------------------

Using IMS, the amounts of several molecules with different *m*/*z* values (mass numbers) were visualized in false colors for various sites, such as CA, adjacent NC, and fibrous and Glisson\'s capsules (Figure [S2](#cas13529-sup-0001){ref-type="supplementary-material"}). Biomolecules detected using the negative ion mode of IMS for human liver samples are listed in Table [2](#cas13529-tbl-0002){ref-type="table-wrap"}. Signals conceivably derived from FA were also detected using the negative ion mode of IMS, as previously reported.[32](#cas13529-bib-0032){ref-type="ref"}, [33](#cas13529-bib-0033){ref-type="ref"}

###### 

Molecule list identified by negative ion mode imaging mass spectrometry

  Name                                   Symbol                  *m*/*z*                                              Adduct        Formula       Signal intensity mean ± SEM (%)                                                                       
  -------------------------------------- ----------------------- ---------------------------------------------------- ------------- ------------- --------------------------------- ---------------------------------------------------- -------------- -----------------------------------------------------
  Palmitic acid                          C16:0                   255.3                                                M−H           C16H32O2      25.0 ± 1.78                       13.6 ± 3.23[a](#cas13529-note-0003){ref-type="fn"}   20.7 ± 3.09    19.6 ± 3.42
  Stearic acid                           C18:0                   283.3                                                M−H           C18H35O2      33.2 ± 3.93                       41.7 ± 2.89                                          31.4 ± 3.46    31.9 ± 3.09
  C‐18MUFA (Oleic acid, vaccenic acid)   C18:1, n‐9 C18:1, n‐7   281.3                                                M−H           C18H34O2      12.3 ± 1.28                       21.4 ± 6.67                                          12.9 ± 2.14    17.8 ± 4.04[a](#cas13529-note-0003){ref-type="fn"}
  Linoleic acid                          C18:2, n‐6              279.3                                                M−H           C18H32O2      22.5 ± 4.31                       17.6 ± 4.24                                          17.4 ± 2.39    20.0 ± 2.71
  Arachidonic acid                       C20:4 n‐6               303.3                                                M−H           C20H32O2      3.9 ± 0.48                        4.2 ± 0.29                                           5.1 ± 0.65     7.3 ± 1.73
  Eicosapentaenoic acid                  C20:5 n‐3               301.3                                                M−H           C20H30O2      1.3 ± 0.44                        1.1 ± 0.48                                           5.1 ± 1.99     2.1 ± 1.00
  Docosahexaenoic acid                   C22:6 n‐3               327.3                                                M−H           C22H32O2      1.8 ± 1.06                        0.5 ± 0.24[a](#cas13529-note-0003){ref-type="fn"}    7.3 ± 6.50     1.2 ± 0.72
  C18:0/C16:0                            1.32 ± 0.13             3.55 ± 0.60[a](#cas13529-note-0003){ref-type="fn"}   1.95 ± 0.34   2.21 ± 0.52                                                                                                         
  C18:1/C18:0                            0.42 ± 0.12             0.56 ± 0.21                                          0.43 ± 0.06   0.68 ± 0.23                                                                                                         
  Phosphatidylinositol                   PI 16:0/18:1            835.6                                                M−H           C43H81O13P    0.77 ± 0.29                       2.99 ± 1.18                                          2.53 ± 1.28    4.88 ± 1.96
  Phosphatidylinositol                   PI 16:0/18:2            833.6                                                M−H           C43H79O13P    0.63 ± 0.17                       0.59 ± 0.17                                          1.31 ± 0.58    2.01 ± 0.78
  Phosphatidylinositol                   PI 16:0/20:4            857.6                                                M−H           C45H79O13P    0.97 ± 0.47                       0.77 ± 0.22                                          0.90 ± 0.25    2.72 ± 0.91
  Phosphatidylinositol                   PI 18:0/18:2            861.6                                                M−H           C45H83O13P    7.89 ± 3.99                       6.52 ± 1.59                                          8.30 ± 1.83    10.44 ± 1.78
  Phosphatidylinositol                   PI 18:0/20:4            885.6                                                M−H           C47H83O13P    84.21 ± 4.99                      72.81 ± 5.16                                         80.93 ± 4.63   68.23 ± 4.57[a](#cas13529-note-0003){ref-type="fn"}
  Phosphatidylinositol                   PI 18:0/20:3            888.6                                                M−H           C47H81O13P    1.65 ± 0.37                       8.21 ± 5.11                                          1.86 ± 0.26    4.66 ± 1.30[a](#cas13529-note-0003){ref-type="fn"}
  Phosphatidylinositol                   PI 18:0/22:6            909.6                                                M−H           C49H83O13P    2.43 ± 0.88                       4.02 ± 1.39                                          2.19 ± 0.33    4.81 ± 0.87[a](#cas13529-note-0003){ref-type="fn"}

Means significantly different from adjacent non‐cancerous parts, *P* \< .05, the Wilcoxon signed‐rank test.

John Wiley & Sons, Ltd

We then investigated SFA and MUFA compositions in 15 HCC samples. PA (C16:0), SA (C18:0) and C18‐MUFA including both OA (C18:1n9) and VA (C18:1n7) were identified in HCC specimens (Figure [1](#cas13529-fig-0001){ref-type="fig"}A‐C). Palmitoleate (C16:1) was not detectable in this experiment. The IMS analysis showed that PA levels were significantly lower, while SA levels were slightly higher in the CA than in the adjacent NC of NHCC, and this change was not observed in the CA or NC of VHCC (Figure [1](#cas13529-fig-0001){ref-type="fig"}A‐C). Correspondingly, SPR was significantly elevated in the CA of NHCC, but not in the CA of VHCC (Figure [1](#cas13529-fig-0001){ref-type="fig"}D). C18‐MUFA levels were higher in the CA than in the NC of both HCC, but a significant difference was only observed in the NC of VHCC. The C18‐MUFA‐to‐SA ratio slightly increased in VHCC and NHCC (Figure [1](#cas13529-fig-0001){ref-type="fig"}E). SPR was more prominently and specifically altered in the CA of NHCC than in the CA of VHCC.

![Saturated fatty acid signals identified by Imaging Mass Spectrometry in hepatocellular carcinoma (HCC). A, Typical reconstruction images acquired from imaging mass spectrometry (IMS) of NHCC (upper 3) and VHCC (lower 3 panels). White dotted lines indicate demarcations between cancerous parts (CA; right lower) and adjacent non‐cancerous parenchyma (NC; left upper). Color variations were made according to the signal intensity of the substrate; blue, rarely existed; pink, abundant. The left panel shows a gross image of the specimen, and the middle and right panels show the abundance of PA and SA, respectively. The scale bar shows 1000 μm. B, Signal intensities, acquired from IMS, of PA (red arrows) and SA (blue arrows) are shown in the upper left (NHCC‐NC), upper right (NHCC ‐CA), lower left (VHCC‐NC) and lower right panels (VHCC‐CA). C, The signal intensity of saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) obtained from all samples, including NHCC (n = 5) and VHCC (n = 10), with comparisons between NC and CA. D, E, The stearate‐to‐palmitate ratio (SPR) (D) and C18‐MUFA ‐to‐stearate ratio (E) in the CA and NC of 5 NHCC and 10 VHCC resected specimens. \**P *\< .05, \*\**P *\< .01 with the Wilcoxon signed‐rank test](CAS-109-1110-g001){#cas13529-fig-0001}

3.3. Expression of ELOVL6, a stearate‐to‐palmitate ratio modulator, was upregulated in NHCC {#cas13529-sec-0017}
-------------------------------------------------------------------------------------------

ELOVL6 is an enzyme that synthesizes SA from PA and regulates cellular SPR. We analyzed ELOVL6 protein expression by immunoblotting and found that ELOVL6 protein levels were markedly higher in the CA than in the NC of NHCC (Figure [2](#cas13529-fig-0002){ref-type="fig"}A,B). However, significant alteration was not observed in *ELOVL6* mRNA expression (Figure [S3](#cas13529-sup-0001){ref-type="supplementary-material"}A). In contrast, no significant differences were observed in ELOVL6 levels between the CA and NC of VHCC. We examined the protein level of stearoyl‐CoA desaturase‐1 (SCD‐1) in NHCC and VHCC because SPR is also influenced by the desaturation of C16:0 and C18:0 by SCD‐1. The results showed that the protein level of SCD‐1 was significantly higher, without elevation of mRNA level (Figure [S3](#cas13529-sup-0001){ref-type="supplementary-material"}B), in the CA than in the NC of VHCC and NHCC (Figure [2](#cas13529-fig-0002){ref-type="fig"}A,C), which is consistent with previous findings.[34](#cas13529-bib-0034){ref-type="ref"}

![Immunoblot analysis for human liver samples and its relationship with the stearate‐to‐palmitate ratio (SPR). A, Immunoblot analysis of ELOVL6 and SCD1 in 15 HCC samples in the cancerous parts (CA) and adjacent non‐cancerous parts (NC). B, C, Densitometry of ELOVL6 (B) and SCD1 (C) expression normalized by beta‐actin, and normalized to that of NC. \**P* \< .05 with the Wilcoxon signed‐rank test. D, E, The relationship between SPR assessed by imaging mass spectrometry (IMS) and ELOVL6 expression in NHCC (D) and VHCC (E). Statistical analyses were performed with Spearman\'s rank correlation coefficient](CAS-109-1110-g002){#cas13529-fig-0002}

We then investigated the relationship between SPR and ELOVL6 protein levels. A correlation was observed between SPR and ELOVL6 protein levels in NHCC parenchyma (*r* ^2^ = .60, *P *= .006; Figure [2](#cas13529-fig-0002){ref-type="fig"}D) but not in VHCC (Figure [2](#cas13529-fig-0002){ref-type="fig"}E).

3.4. Palmitate induced endoplasmic reticulum stress, whereas extrinsic stearate‐to‐palmitate modulation mitigated toxic effects in cell lines {#cas13529-sec-0018}
---------------------------------------------------------------------------------------------------------------------------------------------

To corroborate the importance of increases in SPR in the CA of NHCC, we examined the effects of extracellular FA supplementation on cell stress in cell line experiments. We used Huh7 and HepG2 cells, which are hepatoma cell lines without viral infections. IMS was performed on Huh7 and HepG2 cells and revealed that these cells have different FA compositions. PA (C16:0), SA (18:0) and C18‐MUFA signals were easily detected in the 2 cell lines (Figure [3](#cas13529-fig-0003){ref-type="fig"}A). Endogenous SPR was higher in Huh7 than in HepG2 cells (Figure [3](#cas13529-fig-0003){ref-type="fig"}B). The expression levels of *ELOVL6* and *SCD* mRNA were similar in the 2 cell lines (Figure [3](#cas13529-fig-0003){ref-type="fig"}C). ELOVL6 protein levels in Huh7 cells were also detected using immunofluorescence, which exhibited co‐localization with calnexin, an ER marker (Figure [3](#cas13529-fig-0003){ref-type="fig"}D).

![Fatty acid profile of hepatoma cell lines, Huh7 and HepG2. A, imaging mass spectrometry (IMS) of fatty acids in Huh7 (upper) and HepG2 cells (lower). Red arrows show palmitate (PA) (C16:0) and blue arrows are stearate (SA) (C18:0). B, Stearate‐to‐palmitate ratio (SPR) under normal conditions in Huh7 (red) and HepG2 cells (green). C, Relative expression of the mRNA of *ELOVL6* and *SCD* in Huh7 (red) and HepG2 cells (green). D, Representative immunofluorescence images of ELOVL6 (green) and calnexin (endoplasmic reticulum \[ER\] marker, red) and the nucleus (blue) of Huh7 cells. The scale bar shows 20 μm](CAS-109-1110-g003){#cas13529-fig-0003}

We then investigated changes in the ER stress response influenced by the modulation of exogenous SPR in vitro. Activating transcription factor 3 (*ATF3*), DNA‐damage inducible transcript 3 (*DDIT3*) and splicing form of X‐box binding protein 1 (*XBP1*) are ER stress markers.[31](#cas13529-bib-0031){ref-type="ref"}, [35](#cas13529-bib-0035){ref-type="ref"}, [36](#cas13529-bib-0036){ref-type="ref"} A previous study reported that PA upregulates these transcription factors and cell apoptosis.[14](#cas13529-bib-0014){ref-type="ref"} PA incubation (SPR = 0) upregulated the mRNA expression of *ATF3*,*DDIT3* and *XBP1s* in a dose‐dependent manner in Huh7 (Figure [4](#cas13529-fig-0004){ref-type="fig"}A) and HepG2 cells (Figure [S4](#cas13529-sup-0001){ref-type="supplementary-material"}A), as previously reported. In both cell lines, 600 μmol/L SFA was sufficient to induce a stress response. Therefore, we examined the mechanisms by which SPR modulation affects the ER stress response in vitro. The expression of *ATF3* and *DDIT3* gradually decreased with increases in SPR from 0 (PA 600 μmol/L alone) to 1 (PA 300 μmol/L + SA 300 μmol/L) (Huh7 in Figure [4](#cas13529-fig-0004){ref-type="fig"}A,B and HepG2 in Figure [S4](#cas13529-sup-0001){ref-type="supplementary-material"}A,B). However, further increases in SPR were associated with counter effects, particularly in Huh7 cells (Figure [4](#cas13529-fig-0004){ref-type="fig"}B, compared with HepG2 data in Figure [S4](#cas13529-sup-0001){ref-type="supplementary-material"}B). Consistent with the stronger mRNA expression of ER stress‐associated transcription factors, cleaved caspase 3 and cleaved poly ADP‐ribose polymerase (PARP) protein (a specific 85‐kDa form observed during apoptosis)[37](#cas13529-bib-0037){ref-type="ref"} were downregulated together with SPR modulation from 0 to 1 in the immunoblotting analysis (Huh7 in Figure [4](#cas13529-fig-0004){ref-type="fig"}C,D and HepG2 in Figure [S4](#cas13529-sup-0001){ref-type="supplementary-material"}C,D). No alterations were observed in *ELOVL6* mRNA or protein expression levels between SPR = 0 and SPR = 1 24 hours after the treatment with SFA (Figure [4](#cas13529-fig-0004){ref-type="fig"}C,D and Figure [S4](#cas13529-sup-0001){ref-type="supplementary-material"}C,D). These results suggest that lipotoxic effects are altered not only by the concentration of SFA but also by SPR modulation.

![Endoplasmic reticulum (ER) stress mediated by extracellular fatty acid supplementation in Huh7 cells. A, Quantitative PCR for the mRNA of ER stress‐associated transcription factors and *ELOVL6* after a 24‐hours incubation with saturated fatty acids (SFA). SFA concentrations were modified from 0 to 800 μmol/L with an altered stearate‐to‐palmitate ratio (SPR). SPR = 0 at 800 μmol/L indicates a treatment with 800 μmol/L palmitate (PA), while SPR = 1 at 800 μmol/L means a treatment with 400 μmol/L each of PA and stearate (SA). \**P* \< .05, significant difference in expression between SPR = 0 and SPR = 1 using the paired *t* test. *ATF3*, activating transcription factor 3; *DDIT3*,DNA‐damage inducible transcript 3; and *XBP1*, splicing form of X‐box binding protein 1. B, mRNA expression of ER stress‐associated transcription factors after 24‐hours SFA incubation at a concentration of 600 μmol/L with various SPR (0/600; SPR = 0, 150/450, 300/300; SPR = 1, 450/150 and 600/0) in Huh7 cells. \**P* \< .05 (Bonferroni procedure). C, D, Immunoblot analysis of caspase‐3, poly ADP‐ribose polymerase (PARP), ELOVL6, and beta‐actin with the modulation of SFA concentrations and SPR for 24 hours](CAS-109-1110-g004){#cas13529-fig-0004}

3.5. Silencing ELOVL6 lowered the stearate‐to‐palmitate ratio and increased the endoplasmic reticulum stress response {#cas13529-sec-0019}
---------------------------------------------------------------------------------------------------------------------

We speculated that SPR modulation, from 0 to 1, may be parallel to the process of FA elongation regulated by ELOVL6. Therefore, we examined whether *ELOVL6* silencing decreases SPR. In Huh7 cells, endogenous SPR was decreased to approximately 50% by *ELOVL6* silencing, irrespective of extracellular PA supplementation (Figure [5](#cas13529-fig-0005){ref-type="fig"}A,B), along with reductions in *ELOVL6* mRNA and protein levels (Figure [5](#cas13529-fig-0005){ref-type="fig"}C,D). Similar to the results shown in Figure [4](#cas13529-fig-0004){ref-type="fig"}, extracellular PA supplementation upregulated the mRNA of the ER stress‐associated transcriptional factors, *ATF3* and *DDIT3* (Figure [5](#cas13529-fig-0005){ref-type="fig"}C, compare siControl with siControl+PA). The silencing of *ELOVL6* also increased these mRNA (Figure [5](#cas13529-fig-0005){ref-type="fig"}C). *ATF3* mRNA was upregulated further by *ELOVL6* silencing plus extracellular PA supplementation.

![Silencing *ELOVL6* decreased the stearate‐to‐palmitate ratio (SPR) and increased the endoplasmic reticulum (ER) stress response in Huh7 cells. A, The reconstruction image of IMS for Huh7 cells after a 48‐hours transfection with siRNA and a 24‐hours incubation in the absence or presence of palmitate (PA, 600 μmol/L). The 4 upper and lower panels show images of PA (*m*/*z* 255.3) and SA (*m*/*z* 283.3) contents, respectively. siCtrl, transfected by control siRNA; siE6, transfected by *ELOVL6*‐specific siRNA. B, stearate‐to‐palmitate ratio (SPR) calculated with imaging mass spectrometry (IMS) results. \**P* \< .05, \*\**P *\<.01 with the paired *t* test. C, Expression levels of mRNA by qPCR. siCtrl (open bar), transfected by control siRNA, and siE6 (dotted bar), transfected by *ELOVL6*‐specific siRNA. Red bars (+PA) show the results obtained after a further 24‐hours supplementation with 600 μmol/L PA. \**P* \< .05, \*\**P* \< .01 with the paired *t* test. D, Immunoblot analysis of ELOVL6, protein kinase RNA‐like endoplasmic reticulum kinase (PERK) and its phosphorylated form, caspase‐3 and its cleaved form, poly ADP‐ribose polymerase (PARP) and its cleaved form, SCD1, and beta‐actin](CAS-109-1110-g005){#cas13529-fig-0005}

The phosphorylated form of the RNA protein kinase RNA‐like endoplasmic reticulum kinase (PERK), an ER stress sensor, is known as a pro‐apoptotic factor.[38](#cas13529-bib-0038){ref-type="ref"}, [39](#cas13529-bib-0039){ref-type="ref"} In the immunoblotting analysis, we found that *ELOVL6* silencing increased phosphorylated PERK cooperatively with extracellular PA supplementation. We showed that cleaved caspase‐3 and PARP were upregulated additively by *ELOVL6* silencing and extracellular PA supplementation (Figure [5](#cas13529-fig-0005){ref-type="fig"}D).

Similar results were also obtained for HepG2 cells (Figure [S5](#cas13529-sup-0001){ref-type="supplementary-material"}), indicating that cancer cells escape PA‐induced lipotoxicity by SPR modulation via FA elongation by ELOVL6.

3.6. Cell survival and lipid accumulation caused by silencing ELOVL6 and the palmitate treatment {#cas13529-sec-0020}
------------------------------------------------------------------------------------------------

The results of the immunoblotting analysis indicated that reductions in SPR induce cellular apoptosis. Therefore, we performed a TUNEL assay to clarify whether SPR modulation induces apoptosis in Huh7 cells. *ELOVL6* silencing significantly decreased cell numbers, but increased TUNEL‐positive cell numbers (Figure [6](#cas13529-fig-0006){ref-type="fig"}A‐C). *ELOVL6* silencing reduced lipid droplets in Huh7 cells (Figure [6](#cas13529-fig-0006){ref-type="fig"}A). Cell proliferation was also suppressed by *ELOVL6* silencing (Figure [6](#cas13529-fig-0006){ref-type="fig"}D). Supplementation with 600 μmol/L extracellular PA aggravated these effects (Figure [6](#cas13529-fig-0006){ref-type="fig"}A‐D).

![Cell survival and proliferation after siRNA transfection with or without a palmitate treatment in Huh7 cells. A, Images of the TUNEL assay after a 48‐hours transfection with siRNA and further 24‐hours incubation in the absence or presence of palmitate (palmitate, 600 μmol/L). The scale bar shows 50 μm (4 upper panels). The 4 lower panels show oil staining images by Sudan III. The scale bar shows 20 μm. B, C, The total cell count in a high‐power field (HPF; 400‐fold magnification) (B) and TUNEL‐positive cell count per total cell count (C) in each condition. D, Cell proliferation measured by the XTT assay under each condition. \**P* \< .05, \*\**P* \< .01, using the Bonferroni procedure](CAS-109-1110-g006){#cas13529-fig-0006}

The same results were observed in HepG2 cells (Figure [S6](#cas13529-sup-0001){ref-type="supplementary-material"}). The only difference between Huh7 and HepG2 cells was the absence of lipid droplets when incubated with siControl in the absence of extracellular PA.

4. DISCUSSION {#cas13529-sec-0021}
=============

An increase in morbidity associated with HCC derived from aberrant lipid metabolism, such as NAFL and NASH, is a major public health issue worldwide. Although preventive approaches for HCC through the consumption of MUFA have been reported,[40](#cas13529-bib-0040){ref-type="ref"}, [41](#cas13529-bib-0041){ref-type="ref"} the therapeutic capability of FA for NHCC remains unclear. In the present study, PA concentrations decreased in the CA of NHCC, resulting in the upregulation of SPR. ELOVL6 is known to be upregulated in NASH patients,[42](#cas13529-bib-0042){ref-type="ref"} and the protein expression of this enzyme was elevated in CA of NHCC in the present study. Furthermore, a correlation was observed between ELOVL6 expression and SPR. Because low SPR induces severe lipotoxicity by PA, leading to cell apoptosis via ER stress in hepatoma cell lines, our results suggest that moderate elevations in SPR may avoid cell death and support cancer cell survival.

The results of our in vitro experiments demonstrated that endogenous SPR was distinct in the 2 cell lines examined, suggesting that the appropriate SPR differs in each cell or organ. Huh7 is a hepatocellular carcinoma cell derived from a liver tumor[43](#cas13529-bib-0043){ref-type="ref"} and HepG2 is a hepatoblastoma cell line derived from liver tissue.[44](#cas13529-bib-0044){ref-type="ref"} Therefore, Huh7 may be more similar to the CA of NHCC and a suitable model for the study of NHCC. Huh7 cells had high endogenous SPR, which may have induced sensitivity to high concentrations of SA. These results support previous findings showing that ELOVL6 enhanced deleterious effects on pancreatic β‐cells.[31](#cas13529-bib-0031){ref-type="ref"}, [45](#cas13529-bib-0045){ref-type="ref"}

However, these result reflect the short‐term effects of SPR in vitro, and SPR is also influenced by other factors such as PA synthase; that is, acetyl‐CoA carboxylase (ACC) and FA synthase (FAS),[46](#cas13529-bib-0046){ref-type="ref"} β‐oxidation[47](#cas13529-bib-0047){ref-type="ref"} and food intake. Previous studies demonstrated that SPR decreased with the upregulated expression of ELOVL6 in NASH patients.[42](#cas13529-bib-0042){ref-type="ref"}, [48](#cas13529-bib-0048){ref-type="ref"} These controversial results suggest that SPR is also influenced by other factors and that certain feedback mechanisms regulate SPR in the long term.

Palmitate and SA‐induced lipotoxicity in the liver has been reported in previous studies.[49](#cas13529-bib-0049){ref-type="ref"}, [50](#cas13529-bib-0050){ref-type="ref"}, [51](#cas13529-bib-0051){ref-type="ref"} We herein demonstrated SFA‐induced toxicity in vitro; however, these deleterious effects were altered by changing exogenous SPR under the same total SFA concentration. Free PA and SA are activated by acyl‐CoA synthetase into fatty acyl‐CoA, which are the primary substrates for energy use via β‐oxidation and the synthesis of TG and phospholipids.[52](#cas13529-bib-0052){ref-type="ref"}, [53](#cas13529-bib-0053){ref-type="ref"} We previously reported that lysophosphatidylcholine acyltransferase‐1 (LPCAT1), which specifically incorporates SFA into membrane phosphatidylcholine,[54](#cas13529-bib-0054){ref-type="ref"} regulates the progression of HCC.[55](#cas13529-bib-0055){ref-type="ref"}, [56](#cas13529-bib-0056){ref-type="ref"} Previous studies have demonstrated that elevated membrane saturation caused inflammation and altered signal transduction.[57](#cas13529-bib-0057){ref-type="ref"}, [58](#cas13529-bib-0058){ref-type="ref"}, [59](#cas13529-bib-0059){ref-type="ref"} In TG synthesis, saturated fatty acyl‐CoA is incorporated into lipid droplets,[60](#cas13529-bib-0060){ref-type="ref"}, [61](#cas13529-bib-0061){ref-type="ref"} with substrate specificities.[62](#cas13529-bib-0062){ref-type="ref"}, [63](#cas13529-bib-0063){ref-type="ref"}, [64](#cas13529-bib-0064){ref-type="ref"} This selective usage of SFA may be one of the mechanisms underlying cancer cell survival.

In conclusion, NHCC and hepatoma cell lines may maintain an appropriate SPR to attenuate SFA‐induced lipotoxicity by modulating the ER stress response. Therefore, the modulation of SPR has potential as a therapeutic approach for NHCC.
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